Phase 2, Open-Label Study to Evaluate CC-10004 Recalcitrant (Not Responded to Therapy) Plaque-Type Psoriasis - Contacts and Locations

Phase 2, Open-Label Study to Evaluate CC-10004 Recalcitrant (Not Responded to Therapy) Plaque-Type Psoriasis

This study is ongoing, but not recruiting participants.

Study NCT00521339. Last updated on October 14, 2008. Information provided by Celgene Corporation

Please refer to this study by its ClinicalTrials.gov identifier: NCT00521339

Locations


United States, Massachusetts
	Tufts-New England Medical Center Hospitals
	Boston, Massachusetts, United States, 02111

United States, Missouri
	Central Dermatology
	St. Louis, Missouri, United States, 63117

United States, Oregon
	Oregon Medical Research Center, P.C.
	Portland, Oregon, United States, 97223

United States, Texas
	Baylor Research Institute
	Dallas, Texas, United States, 75246-1613

Sponsors and Collaborators

Celgene Corporation

Investigators


Principal Investigator:	Craig Leonardi, MD	Central Dermatology

Principal Investigator:	Alan Menter, MD	Baylor Research Institute

Principal Investigator:	Alice Gottlieb, MD., Ph.D.	Tufts Medical Center

Principal Investigator:	Robert T Matheson, MD	Oregon Medical Research Center, P.C